Terms: = Prostate cancer AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3
60348 results:
1. Do alpha blockers reduce the risk of urinary retention post-transperineal prostate biopsy? A systematic narrative review.
Alhamdani Z; Poppenbeek S; Bolton D; Wong LM; Sethi K
World J Urol; 2024 May; 42(1):332. PubMed ID: 38758413
[TBL] [Abstract] [Full Text] [Related]
2. Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in prostate cancer.
Hu C; Qiao X; Huang R; Hu C; Bao J; Wang X
Radiol Imaging Cancer; 2024 May; 6(3):e230143. PubMed ID: 38758079
[TBL] [Abstract] [Full Text] [Related]
3. prostate intra-fraction motion recorded by transperineal ultrasound.
Ballhausen H; Belka C; Li M
Sci Data; 2024 May; 11(1):504. PubMed ID: 38755158
[TBL] [Abstract] [Full Text] [Related]
4. Determinants and Factors of Physical Activity After Oncology Treatments (DEFACTO) in Metropolitan France: Protocol of a Mixed Methods Study and Intervention.
Aumaitre A; Gagnayre R; Foucaut AM
JMIR Res Protoc; 2024 May; 13():e52274. PubMed ID: 38753415
[TBL] [Abstract] [Full Text] [Related]
5. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed prostate cancer.
Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
[TBL] [Abstract] [Full Text] [Related]
6. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
[TBL] [Abstract] [Full Text] [Related]
7. The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging score.
Baudewyns A; Guenzel K; Halinski A; Dariane C; Delavar G; Anract J; Barry Delongchamps N; Jabbour T; Bourgeno HA; Lefebvre Y; Ferriero M; Simone G; Fourcade A; Fournier G; Oderda M; Gontero P; Bernal-Gomez A; Mastrorosa A; Roche JB; Zahr RA; Ploussard G; Fiard G; Rysankova K; Bui AP; Taha F; Windisch O; Benamran D; Vlahopoulos L; Assenmacher G; Roumeguère T; Peltier A; Diamand R
World J Urol; 2024 May; 42(1):322. PubMed ID: 38747982
[TBL] [Abstract] [Full Text] [Related]
8. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
Quintanilha JCF; Sibley AB; Liu Y; Niedzwiecki D; Halabi S; Rogers L; O'Neil B; Kindler H; Kelly W; Venook A; McLeod HL; Ratain MJ; Nixon AB; Innocenti F; Owzar K
BMC Genomics; 2024 May; 25(1):473. PubMed ID: 38745123
[TBL] [Abstract] [Full Text] [Related]
9. Diabetes-related risk factors and survival among individuals with type 2 diabetes and breast, lung, colorectal, or prostate cancer.
Laurberg T; Witte DR; Gudbjörnsdottir S; Eliasson B; Bjerg L
Sci Rep; 2024 May; 14(1):10956. PubMed ID: 38740921
[TBL] [Abstract] [Full Text] [Related]
10. CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.
Azur RAG; Olarte KCV; Ybañez WS; Ocampo AMM; Bagamasbad PD
PLoS One; 2024; 19(5):e0300413. PubMed ID: 38739593
[TBL] [Abstract] [Full Text] [Related]
11. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study.
Scilipoti P; Liedberg F; Garmo H; Wilberg Orrason A; Stattin P; Westerberg M
Scand J Urol; 2024 May; 59():98-103. PubMed ID: 38738332
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of prostate cancer Cell Survival and Proliferation by Carnosic Acid Is Associated with Inhibition of Akt and Activation of AMPK Signaling.
Nadile M; Sze NSK; Fajardo VA; Tsiani E
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732504
[TBL] [Abstract] [Full Text] [Related]
13. CYP7B1 as a Biomarker for prostate cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in prostate cancer Patients-Diamond Study).
Russo GI; Durukan E; Asmundo MG; Lo Giudice A; Salzano S; Cimino S; Rescifina A; Fode M; Abdelhameed AS; Caltabiano R; Broggi G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731981
[TBL] [Abstract] [Full Text] [Related]
14. Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on cancer Cell Lines.
Albani M; Fassi EMA; Moretti RM; Garofalo M; Montagnani Marelli M; Roda G; Sgrignani J; Cavalli A; Grazioso G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731842
[TBL] [Abstract] [Full Text] [Related]
15. A cross-sectional study of ERG expression and the relationship with clinicopathological features of prostate cancer in Southwestern Uganda.
Mitala Y; Ssenkumba B; Birungi A; Kiconco R; Mutakooha MM; Atwine R
Diagn Pathol; 2024 May; 19(1):67. PubMed ID: 38730435
[TBL] [Abstract] [Full Text] [Related]
16. Increasing the radiation-induced cytotoxicity by silver nanoparticles and docetaxel in prostate cancer cells.
Hatami Zharabad S; Mohammadian M; Zohdi Aghdam R; Hassanzadeh Dizaj M; Behrouzkia Z
Mol Biol Rep; 2024 May; 51(1):633. PubMed ID: 38724835
[TBL] [Abstract] [Full Text] [Related]
17. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract] [Full Text] [Related]
18. Vikil
Tettey CO; Essuman EK; Aninagyei E; Kwansa-Bentum HT; Agyemang Boakye A; Kortei NK; Boamah D
Integr Cancer Ther; 2024; 23():15347354241253846. PubMed ID: 38721848
[TBL] [Abstract] [Full Text] [Related]
19. Novel role of LLGL2 silencing in autophagy: reversing epithelial-mesenchymal transition in prostate cancer.
Hong GL; Kim KH; Kim YJ; Lee HJ; Cho SP; Han SY; Yang SW; Lee JS; Kang SK; Lim JS; Jung JY
Biol Res; 2024 May; 57(1):25. PubMed ID: 38720397
[TBL] [Abstract] [Full Text] [Related]
20. Treatment Related Acute Toxicities Between Treatment with 3D-CRT and IMRT in Localised prostate cancer.
Hanif S; Osmani AH; Mallick J
J Coll Physicians Surg Pak; 2024 May; 34(5):573-577. PubMed ID: 38720219
[TBL] [Abstract] [Full Text] [Related]
[Next]